Journal: Cells

Article Title: Quetiapine Ameliorates MIA-Induced Impairment of Sensorimotor Gating: Focus on Neuron-Microglia Communication and the Inflammatory Response in the Frontal Cortex of Adult Offspring of Wistar Rats

doi: 10.3390/cells11182788

Figure Lengend Snippet: The groups of the offspring generated and subsequently subjected to the administration of the antipsychotic drugs. The number of animals in each group is reported.

Article Snippet: Quetiapine (Carbosynth, Berkshire, UK) was prepared as a 10 mg/kg solution in 0.8% acetic acid in 1 mL of saline (pH adjusted with 1 N NaOH) [ , ].

Techniques: Generated, Control

Journal: Cells

Article Title: Quetiapine Ameliorates MIA-Induced Impairment of Sensorimotor Gating: Focus on Neuron-Microglia Communication and the Inflammatory Response in the Frontal Cortex of Adult Offspring of Wistar Rats

doi: 10.3390/cells11182788

Figure Lengend Snippet: The impact of 14-day intraperitoneal administration of chlorpromazine, quetiapine or aripiprazole on the prepulse inhibition (PPI) of the acoustic startle response in the control and prenatally LPS-exposed offspring in adulthood. The numbers of animals in the cohorts were as follows: n = 4–13 (chlorpromazine), n = 9 (quetiapine) and n = 7 (aripiprazole) in each group. The results are presented as the means of the percentage of PPI (%PPI) calculated from the maximum startle response (V max ) ( A ) and average startle amplitude (AVG) ( B ) induced by each prepulse intensity ± SEM. # p < 0.05 vs. LPS + vehicle group.

Article Snippet: Quetiapine (Carbosynth, Berkshire, UK) was prepared as a 10 mg/kg solution in 0.8% acetic acid in 1 mL of saline (pH adjusted with 1 N NaOH) [ , ].

Techniques: Inhibition, Control

Journal: Cells

Article Title: Quetiapine Ameliorates MIA-Induced Impairment of Sensorimotor Gating: Focus on Neuron-Microglia Communication and the Inflammatory Response in the Frontal Cortex of Adult Offspring of Wistar Rats

doi: 10.3390/cells11182788

Figure Lengend Snippet: The impact of prenatal exposure to LPS and subsequent chronic treatment with chlorpromazine ( A ), quetiapine ( B ) or aripiprazole ( C ) on Cx3cl1 , Cx3cr1 , Cd200 or Cd200r gene expression in the frontal cortices of the offspring. The mRNA levels were measured using qRT-PCR with n = 4–6 (chlorpromazine), n = 5–9 (quetiapine) and n = 5–6 (aripiprazole) in each group. The results are presented as the average fold change ± SEM. * p < 0.05 vs. control + vehicle group.

Article Snippet: Quetiapine (Carbosynth, Berkshire, UK) was prepared as a 10 mg/kg solution in 0.8% acetic acid in 1 mL of saline (pH adjusted with 1 N NaOH) [ , ].

Techniques: Gene Expression, Control

Journal: Cells

Article Title: Quetiapine Ameliorates MIA-Induced Impairment of Sensorimotor Gating: Focus on Neuron-Microglia Communication and the Inflammatory Response in the Frontal Cortex of Adult Offspring of Wistar Rats

doi: 10.3390/cells11182788

Figure Lengend Snippet: The impact of prenatal exposure to LPS and subsequent chronic treatment with chlorpromazine ( A ), quetiapine ( B ) or aripiprazole ( C ) on Cd40 , Cd68 , Arg1 and Igf-1 gene expression in the frontal cortices of the offspring. The mRNA levels were measured using qRT-PCR with n = 4–6 (chlorpromazine), n = 6–9 (quetiapine) and n = 5–6 (aripiprazole) in each group. The results are presented as the average fold change ± SEM. * p < 0.05 vs. control + vehicle group, # p < 0.05 vs. LPS + vehicle group.

Article Snippet: Quetiapine (Carbosynth, Berkshire, UK) was prepared as a 10 mg/kg solution in 0.8% acetic acid in 1 mL of saline (pH adjusted with 1 N NaOH) [ , ].

Techniques: Gene Expression, Control

Journal: Cells

Article Title: Quetiapine Ameliorates MIA-Induced Impairment of Sensorimotor Gating: Focus on Neuron-Microglia Communication and the Inflammatory Response in the Frontal Cortex of Adult Offspring of Wistar Rats

doi: 10.3390/cells11182788

Figure Lengend Snippet: The impact of prenatal exposure to LPS and subsequent chronic treatment with chlorpromazine ( n = 4–6 in each group), quetiapine ( n = 6 in each group) or aripiprazole ( n = 6–7 in each group) on the levels of the proinflammatory proteins (IL-1β, IL-6 and TNF-α) in the frontal cortices of the offspring. The results are presented as the mean ± SEM. * p < 0.05 vs. control + vehicle.

Article Snippet: Quetiapine (Carbosynth, Berkshire, UK) was prepared as a 10 mg/kg solution in 0.8% acetic acid in 1 mL of saline (pH adjusted with 1 N NaOH) [ , ].

Techniques: Control

Journal: Cells

Article Title: Quetiapine Ameliorates MIA-Induced Impairment of Sensorimotor Gating: Focus on Neuron-Microglia Communication and the Inflammatory Response in the Frontal Cortex of Adult Offspring of Wistar Rats

doi: 10.3390/cells11182788

Figure Lengend Snippet: The impact of prenatal exposure to LPS and subsequent chronic treatment with chlorpromazine ( n = 4–6 in each group), quetiapine ( n = 6 in each group) or aripiprazole ( n = 6–7 in each group) on the levels of the anti-inflammatory proteins (IL-4 and IL-10) in the frontal cortices of the offspring. The results are presented as the mean ± SEM. * p < 0.05 vs. control + vehicle.

Article Snippet: Quetiapine (Carbosynth, Berkshire, UK) was prepared as a 10 mg/kg solution in 0.8% acetic acid in 1 mL of saline (pH adjusted with 1 N NaOH) [ , ].

Techniques: Control

Journal: Cells

Article Title: Quetiapine Ameliorates MIA-Induced Impairment of Sensorimotor Gating: Focus on Neuron-Microglia Communication and the Inflammatory Response in the Frontal Cortex of Adult Offspring of Wistar Rats

doi: 10.3390/cells11182788

Figure Lengend Snippet: The impact of prenatal exposure to LPS and subsequent chronic treatment with quetiapine on the gene expression of Cx3cl1 , Cx3cr1 , Cd200 and Cd200r ( A ) as well as Cd40 , Cd68 , Arg1 and Igf-1 ( B ) in the hippocampi of the offspring. The mRNA levels were measured using qRT-PCR with n = 7–8 in each group. The results are presented as the average fold change ± SEM.

Article Snippet: Quetiapine (Carbosynth, Berkshire, UK) was prepared as a 10 mg/kg solution in 0.8% acetic acid in 1 mL of saline (pH adjusted with 1 N NaOH) [ , ].

Techniques: Gene Expression, Control

Journal: The Journal of toxicological sciences

Article Title: Novel risk assessment of reactive metabolites from discovery to clinical stage.

doi: 10.2131/jts.44.201

Figure Lengend Snippet: Fig. 4. The postulated structures of reactive metabolites and their adducts with trapping agents. (diclofenac, quetiapine and rimona- bant)

Article Snippet: Quetiapine fumarate was purchased from Toronto Research Chemicals (North York, Canada).

Techniques:

Journal: Acta Neuropathologica Communications

Article Title: Clobetasol promotes remyelination in a mouse model of neuromyelitis optica

doi: 10.1186/s40478-016-0309-4

Figure Lengend Snippet: Compounds with reported remyelinating activity

Article Snippet: Test drugs included clobetasol, miconazole, benztropine, clemastine, fumarate, retinoic acid and citicolone (Sigma-Aldrich, St. Louis, MO, USA), enprofylline, olesoxime and quetiapine fumarate (Santa Cruz Biotechnology, Dallas, TX, USA), GC-1 and quercetin (Tocris Bioscience, Bristol, UK), fasudil (Tszchem, Lexington, MA, USA), and Y-27632 (BD Biosciences, San Jose, CA, USA); Triiodothyronine (T3, Calbiochem, Billerica, MA, USA) was used as positive control.

Techniques: Ex Vivo, Inhibition

Journal: Journal of Analytical Toxicology

Article Title: Norbuprenorphine Interferences in Urine Drug Testing LC–MS-MS Confirmation Methods from Quetiapine Metabolites

doi: 10.1093/jat/bkab113

Figure Lengend Snippet: Structures of commercially available standards for buprenorphine, quetiapine and their respective urinary metabolites.

Article Snippet: For quetiapine metabolite characterization experiments, quetiapine, 7-hydroxyquetiapine and quetiapine acid were also acquired from Cerilliant, and quetiapine sulfoxide was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).

Techniques:

Journal: Journal of Analytical Toxicology

Article Title: Norbuprenorphine Interferences in Urine Drug Testing LC–MS-MS Confirmation Methods from Quetiapine Metabolites

doi: 10.1093/jat/bkab113

Figure Lengend Snippet: Chromatograms (with same y -axis scaling) showing norbuprenorphine interferences observed in patient specimens. (2A) Patient negative for norbuprenorphine, (2B) patient positive for norbuprenorphine, (2C) patient positive for norbuprenorphine and quetiapine, (2D) patient positive for quetiapine and (2E) norbuprenorphine at the LLOQ (10 ng/mL).

Article Snippet: For quetiapine metabolite characterization experiments, quetiapine, 7-hydroxyquetiapine and quetiapine acid were also acquired from Cerilliant, and quetiapine sulfoxide was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).

Techniques:

Journal: Journal of Analytical Toxicology

Article Title: Norbuprenorphine Interferences in Urine Drug Testing LC–MS-MS Confirmation Methods from Quetiapine Metabolites

doi: 10.1093/jat/bkab113

Figure Lengend Snippet: Q-Exactive HRAM extracted mass chromatograms from a patient positive for norbuprenorphine and quetiapine showing resolution by m / z and retention time of each of the quetiapine metabolites (3A) from norbuprenorphine (3B).

Article Snippet: For quetiapine metabolite characterization experiments, quetiapine, 7-hydroxyquetiapine and quetiapine acid were also acquired from Cerilliant, and quetiapine sulfoxide was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).

Techniques:

Journal: Journal of Analytical Toxicology

Article Title: Norbuprenorphine Interferences in Urine Drug Testing LC–MS-MS Confirmation Methods from Quetiapine Metabolites

doi: 10.1093/jat/bkab113

Figure Lengend Snippet: Chromatograms (with same y-axis scaling) showing the elimination of norbuprenorphine interferences using alternative MRM transitions. (4A) Patient negative for norbuprenorphine, (4B) patient positive for norbuprenorphine, (4C) patient positive for norbuprenorphine and quetiapine, (4D) patient positive for quetiapine and (4E) norbuprenorphine at the LLOQ (10 ng/mL).

Article Snippet: For quetiapine metabolite characterization experiments, quetiapine, 7-hydroxyquetiapine and quetiapine acid were also acquired from Cerilliant, and quetiapine sulfoxide was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).

Techniques:

Journal: Clinical drug investigation

Article Title: Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients

doi: 10.1007/s40261-016-0439-2

Figure Lengend Snippet: Assessment of liver injury markers during the study period. a ALT assessment. #Elevated group patients showed robust differences R2 = 0.442 in ALT levels during the medication time-course at p = 0.001. *Significant contrast in the treatment course between the baseline elevated and non-elevated groups of the quetiapine arm F(3,82) = 10.437, p < 0.01 (F statistics). **There was a significant Time × Treatment × Liver-injury group interaction. b AST assessment. There was no significant elevation in association determined between AST levels through the treatment course of the quetiapine arm. Time by Treatment repeated analysis of variance statistical test was used. Data are presented as mean ± standard error. *Statistical significance was set at p ≤ 0.05. Non-elevated group from baseline. Gr.2 elevated group from baseline. Q in Quetiapine treatment group. P in Placebo treatment group. ALT normal range 6–40 IU/L; AST normal range 10–34 IU/L

Article Snippet: 2.2 Procedures and Assessments The active drug, quetiapine XR (Seroquel XR® AstraZeneca, Wilmington, DE, USA), was provided to the participants for 3 months in 50- and 200-mg tablets with identical matching non-active pills for the placebo group titrated with a full dose of 400 mg/day [ 28 ] (in a dose-escalating manner reaching a plateau phase during week 4).

Techniques:

Journal: Clinical drug investigation

Article Title: Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients

doi: 10.1007/s40261-016-0439-2

Figure Lengend Snippet: Patient demographics and timeline for last 90 days for drinking history collected at baseline by treatment arm and sex

Article Snippet: 2.2 Procedures and Assessments The active drug, quetiapine XR (Seroquel XR® AstraZeneca, Wilmington, DE, USA), was provided to the participants for 3 months in 50- and 200-mg tablets with identical matching non-active pills for the placebo group titrated with a full dose of 400 mg/day [ 28 ] (in a dose-escalating manner reaching a plateau phase during week 4).

Techniques:

Journal: Clinical drug investigation

Article Title: Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients

doi: 10.1007/s40261-016-0439-2

Figure Lengend Snippet: Serum triglyceride and fasting blood glucose evaluation of study participants by Time and Treatment. Within the quetiapine arm, triglyceride levels were higher in patients with baseline liver injury, and showed significant between-subjects effects at each time-point, p = 0.041, when TD90 was co-varied. *Significant time × treatment effect in observed in glucose level in quetiapine arm, p = 0.054, post hoc test showed an effect at 13 W. Time by Treatment repeated analysis of variance statistical test was used. Data are presented as mean ± standard error. *Statistical significance was set at p ≤ 0.05. Gr.1 Non-elevated group from baseline. Gr.2 Elevated group from baseline. Q in Quetiapine treatment group. P in Placebo treatment group. Triglycerides: normal <150, borderline-high range 150–199, high triglycerides range 200–499, and very high triglycerides ≥500. Normal fasting blood glucose (FBG) range was 60–115 mg/dl

Article Snippet: 2.2 Procedures and Assessments The active drug, quetiapine XR (Seroquel XR® AstraZeneca, Wilmington, DE, USA), was provided to the participants for 3 months in 50- and 200-mg tablets with identical matching non-active pills for the placebo group titrated with a full dose of 400 mg/day [ 28 ] (in a dose-escalating manner reaching a plateau phase during week 4).

Techniques:

Journal: Clinical drug investigation

Article Title: Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients

doi: 10.1007/s40261-016-0439-2

Figure Lengend Snippet: Hepatotoxicity report from published articles of second-generation antipsychotic drugs in human subjects. Our study was conducted in patients who were actively drinking and had a heavy drinking profile

Article Snippet: 2.2 Procedures and Assessments The active drug, quetiapine XR (Seroquel XR® AstraZeneca, Wilmington, DE, USA), was provided to the participants for 3 months in 50- and 200-mg tablets with identical matching non-active pills for the placebo group titrated with a full dose of 400 mg/day [ 28 ] (in a dose-escalating manner reaching a plateau phase during week 4).

Techniques: